Roivant Sciences (ROIV) grants director Oren Ilan 775 fully vested shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Oren Ilan received an award of 775 Common Shares on July 17, 2026 at $0.0000 per share under the company’s Non-Employee Director Compensation Plan, fully vested as of the grant date.

After this grant, Ilan directly holds 121,004 Common Shares; the transaction is reported as a grant/award acquisition and was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 775 shares

Net Buy 1 txn

Insider Oren Ilan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	775	$0.00	$0.00

Holdings After Transaction: Common Shares — 121,004 shares (Direct)

Footnotes (1)

1. F1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Key Figures

Shares awarded: 775.0000 shares Price per share: $0.0000 per share Shares owned after grant: 121004.0000 shares +1 more

4 metrics

Shares awarded 775.0000 shares Common Shares granted to director Oren Ilan on 2026-07-17

Price per share $0.0000 per share Stated grant price for the 775 Common Shares

Shares owned after grant 121004.0000 shares Total direct Common Shares held by Oren Ilan following the award

Transaction date 2026-07-17 Date of the Common Share award to director Oren Ilan

Key Terms

Non-Employee Director Compensation Plan, Common Shares, grant/award acquisition, Rule 10b5-1 trading plan

4 terms

Non-Employee Director Compensation Plan financial

"received pursuant to the Issuer's Non-Employee Director Compensation Plan"

Common Shares financial

"Reflects an award of Common Shares received pursuant to the Issuer's"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Rule 10b5-1 trading plan regulatory

"The transaction was not made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 09:00 PM Accepted by SEC EDGAR 07/21/2026 - 09:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Roivant Sciences (ROIV) director Oren Ilan report?

Director Oren Ilan reported receiving an equity award of 775 Roivant Sciences Common Shares. The shares were granted as compensation under the Non-Employee Director Compensation Plan and were fully vested immediately, increasing his direct ownership stake in the company.

How many Roivant Sciences (ROIV) shares does director Oren Ilan own after this award?

Following the award, Oren Ilan directly holds 121,004 Roivant Sciences Common Shares. This figure reflects his total direct ownership position immediately after receiving the fully vested 775-share grant under the company’s Non-Employee Director Compensation Plan.

What were the terms of Oren Ilan’s 775-share award at Roivant Sciences (ROIV)?

The award to Oren Ilan consisted of 775 Common Shares at a stated price of $0.0000 per share. It was granted under Roivant Sciences’ Non-Employee Director Compensation Plan and was fully vested as of the grant date, providing immediate ownership.

Was Oren Ilan’s Roivant Sciences (ROIV) share award under a Rule 10b5-1 trading plan?

The reported transaction was not made under a Rule 10b5-1 trading plan. The filing’s trading-plan checkbox is unchecked, indicating the grant was standard director compensation rather than executed pursuant to a pre-arranged trading plan.

What plan governs the 775-share award to Roivant Sciences (ROIV) director Oren Ilan?

The 775-share award was granted under Roivant Sciences’ Non-Employee Director Compensation Plan. According to the disclosure, the Common Shares received pursuant to this plan were fully vested as of the grant date, giving Ilan immediate, unrestricted ownership of the awarded shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oren Ilan

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/17/2026		A		775(1)	A	$0(1)	121,004	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Ilan Oren	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)